The Oncolytic Viruses market growth is driven by factors like increase in the prevalence of Oncolytic Viruses, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Oncolytic Viruses market report also offers comprehensive insights into the Oncolytic Viruses market size, share, Oncolytic Viruses epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Oncolytic Viruses market size growth forward.
Some of the key highlights from the Oncolytic Viruses Market Insights Report:
-
Several key pharmaceutical companies, including Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others, are developing novel products to improve the Oncolytic Viruses treatment outlook.
-
In July 2024, KaliVir Immunotherapeutics, Inc., a biotech company specializing in developing innovative, multi-mechanistic oncolytic viral immunotherapy programs, announced that the FDA has approved its Investigational New Drug (IND) application for the STEALTH-001 study of VET3-TGI in patients with advanced, incurable solid tumors.
-
In March 2024, Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, announced the successful completion of the first cohort in its Phase 1 clinical trial of the CD19 oncolytic virotherapy candidate onCARlytics (on-CAR-19, CF33-CD19 HOV4) in the intratumoral monotherapy arm. As a result, the trial is now set to proceed with combination dosing using the CD19-targeting drug blinatumomab (Blincyto®, marketed by Amgen) for patients with solid tumors.
-
The United States holds the largest share of the Oncolytic Virus market, representing over 70% of the total market, in contrast to regions like the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. Compared to other tumor immunotherapies, oncolytic viruses offer several advantages, including high efficiency in killing cancer cells, precise targeting, and fewer side effects or drug resistance.
-
Currently, only two oncolytic virus therapies have been approved: IMLYGIC (Talimogene laherparepvec/T-VEC; Amgen), which was approved in the US, Europe, and Japan in 2015, and DELYTACT (teserpaturev/G47∆; Daiichi Sankyo), which was approved in Japan in 2021. The oncolytic virus pipeline remains strong, with major pharmaceutical companies such as Replimune, Genelux, Imugene, and EpicentRx conducting active research to expand cancer treatment options.
-
Among all emerging therapies, RP1 stands out as the most promising, expected to capture around 40% of the market over the next decade due to its high efficacy. In November 2023, Genelux announced that the US FDA granted Fast Track designation (FTD) for its Olvi-Vec (olvimulogene nanivacirepvec) development program for treating patients with platinum-resistant or refractory ovarian cancer.
-
As per DelveInsight analysis, the Oncolytic Viruses market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Oncolytic Viruses Market Landscape
Oncolytic Viruses Overview
Oncolytic viruses are a type of anti-cancer therapy that help reduce tumors by replicating preferentially within tumor cells, inducing immunogenic cell death, and activating the body’s immune response against the tumor. These viruses, whether native or engineered, are used to target and destroy cancer cells.
Though not fully understood, oncolytic viruses eliminate tumor cells through two primary mechanisms: direct destruction of infected cells (oncolysis) and indirectly enhancing the host’s immune response to fight the tumor.
Oncolytic viruses can be either RNA or DNA viruses. RNA viruses, such as reoviruses, paramyxoviruses, and picornaviruses, typically encode a small number of genes and replicate quickly, leading to rapid tumor cell destruction. In contrast, DNA oncolytic viruses like herpes viruses, adenoviruses, or poxviruses can accommodate multiple foreign genes but replicate and amplify more slowly.
Do you know the treatment paradigms for different countries? Download our Oncolytic Viruses Market Sample Report
Oncolytic Viruses Epidemiology Insights
-
According to GLOBOCAN, the number of breast cancer cases in the United States is projected to increase from 274,375 in 2022 to 341,295 by 2035.
-
DelveInsight’s analysis indicates that prostate cancer represented nearly 20% of the overall target patient population for oncolytic virus therapies in 2023 across the 7MM (the seven major markets).
Oncolytic Viruses Epidemiology Segmentation
DelveInsight’s Oncolytic Viruses market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Oncolytic Viruses historical patient pools and forecasted Oncolytic Viruses patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Oncolytic Viruses Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:
-
Oncolytic Viruses Prevalence
-
Age-Specific Oncolytic Viruses Prevalence
-
Gender-Specific Oncolytic Viruses Prevalence
-
Diagnosed and Treatable Cases of Oncolytic Viruses
Visit for more @ Oncolytic Viruses Epidemiological Insights
Oncolytic Viruses Market Outlook
As cancer remains a leading cause of death globally, the need for innovative therapies to effectively target and destroy cancer cells is becoming more urgent. Oncolytic viruses, which have the unique ability to selectively infect and replicate within tumor cells, have emerged as a promising approach in cancer treatment. Factors such as increased research and development, growing investments from pharmaceutical companies, and an expanding pipeline of clinical trials are driving market growth.
With continued advancements and strategic partnerships, oncolytic viruses are set to play a significant role in the future of oncology, offering patients new hope and supporting the development of more effective and personalized cancer therapies.
In 2015, IMLYGIC (talimogene laherparepvec/T-Vec; Amgen) became the first oncolytic virus approved by the US FDA and later by the European Commission (EC) for treating unresectable melanoma lesions. This therapy utilizes a genetically modified Herpes Simplex Virus Type 1 (HSV-1) to replicate inside tumors and activate the immune system.
In 2021, DELYTACT (teserpaturev/G47∆; Daiichi Sankyo) received conditional approval in Japan as the first oncolytic virus for malignant glioma. Its triple mutation within the viral genome enhances tumor cell replication and stimulates a stronger immune response.
Despite these achievements, ongoing development of oncolytic virus therapies continues through clinical trials by major players such as Replimune, DNAtrix, and SillaJen, pointing to a promising future for oncolytic virotherapy in treating various cancers worldwide.
Oncolytic Viruses Marketed Drugs
-
IMLYGIC (T-VEC): Amgen
-
DELYTACT (G47Δ): Daiichio Sankyo
Oncolytic Viruses Emerging Drugs
-
Olvi-Vec: Genelux
-
RP1: Replimune
Oncolytic Viruses Key Companies
-
Targovax, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichio Sankyo, and others
For more information, visit Oncolytic Viruses Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Oncolytic Viruses Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Oncolytic Viruses, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Oncolytic Viruses epidemiology in the 7MM
-
Oncolytic Viruses marketed and emerging therapies
-
Oncolytic Viruses companies
-
Oncolytic Viruses market drivers and barriers
Table of Contents:
1 Oncolytic Viruses Market Key Comprehensive Insights
2 Oncolytic Viruses Market Report Introduction
3 Competitive Intelligence Analysis for Oncolytic Viruses
4 Oncolytic Viruses Market Analysis Overview at a Glance
5 Executive Summary of Oncolytic Viruses
6 Oncolytic Viruses Epidemiology and Market Methodology
7 Oncolytic Viruses Epidemiology and Patient Population
8 Oncolytic Viruses Patient Journey
9 Oncolytic Viruses Treatment Algorithm, Oncolytic Viruses Current Treatment, and Medical Practices
10 Key Endpoints in Oncolytic Viruses Clinical Trials
11 Oncolytic Viruses Marketed Therapies
12 Oncolytic Viruses Emerging Therapies
13 Oncolytic Viruses: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Oncolytic Viruses
16 Oncolytic Viruses Market Key Opinion Leaders Reviews
18 Oncolytic Viruses Market Drivers
19 Oncolytic Viruses Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Oncolytic Viruses Epidemiology 2034
DelveInsight’s “Oncolytic Viruses – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Oncolytic Viruses epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Oncolytic Viruses Pipeline 2024
“Oncolytic Viruses Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Oncolytic Viruses market. A detailed picture of the Oncolytic Viruses pipeline landscape is provided, which includes the disease overview and Oncolytic Viruses treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/